Clinical Study on the Preservation of Ovarian Function Following Autologous Hematopoietic Stem Cell Transplantation Using Goserelin

NCT07552493 | Not Yet Recruiting

• 1 other identifier: UHCT260112
• Study Type: interventional
• Target: 64
• Locations: 1 country
• Sites: 5

Brief Summary

This study is a prospective, multicenter, randomized controlled clinical trial planned to enroll 64 female hematologic patients aged 14 to 50 years scheduled for autologous hematopoietic stem cell transplantation (auto-HSCT). Participants will be divided into two groups based on the use of myeloablative conditioning: the myeloablative conditioning (MAC) group and the non-MAC conditioning group. The conditioning regimen for autologous hematopoietic stem cell transplantation primarily employs melphalan. A melphalan dose \>140 mg/m² constitutes myeloablative conditioning (MAC), while a dose ≤140 mg/m² is classified as non-myeloablative conditioning. Within each group, patients were randomly assigned 1:1 to the experimental group (goserelin prophylaxis) or control group using a random number table. The experimental group received a single 3.6mg subcutaneous injection of goserelin 1-3 days prior to conditioning, in addition to the standard transplantation regimen. The control group did not receive goserelin prophylaxis. The primary endpoint was menstrual recovery rate at 6 months post-transplantation (defined as ≥3 naturally occurring menstrual cycles without intervention by menstrual-regulating drugs). Secondary endpoints included: incidence of premature ovarian insufficiency (POI); ovarian reserve function markers: anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2) levels; Other reproductive parameters: ovarian and uterine volume, endometrial thickness; time to neutrophil/platelet engraftment; disease recurrence rate; transplant-related mortality; and adverse event (AE) incidence. This study aims to evaluate the efficacy of goserelin in improving ovarian function following autologous hematopoietic stem cell transplantation in hematologic malignancy patients.

Conditions

Ovarian Insufficiency; Autologous Hematopoietic Stem Cell Transplantation

Keywords

Autologous haematopoietic stem cell transplantation; Ovarian insufficiency

Outcome Measures

Primary Outcomes (1)

• Menstrual recovery rate six months after transplantation

  Menstrual recovery rate at 6 months post-transplant, defined as the natural restoration of menstrual cycles ≥3 times without pharmacological intervention.

  month 6

Secondary Outcomes (1)

• Ovarian function; Safety

  month 6

Study Arms (2)

Goserelin group

EXPERIMENTAL

Drug: Goserelin 3.6 MG

Control group

NO INTERVENTION

Interventions

Goserelin 3.6 MG DRUG

Subcutaneous injection of 3.6 mg of goserelin acetate once, administered 1 to 3 days prior to autologous haematopoietic stem cell transplantation conditioning.

Goserelin group

Eligibility Criteria

• Age: 14 Years - 50 Years
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• \. Haematological patients scheduled for autologous haematopoietic stem cell transplantation; 2. Female patients aged 14 to 50 years with regular menstrual cycles prior to transplantation; 3. Patients or their legal representatives must voluntarily participate and sign an informed consent form, demonstrating comprehension and willingness to comply with all study procedures and requirements; 4. Estimated survival exceeding one year to ensure sufficient time for monitoring menstrual recovery.

You may not qualify if:

• \. Patients with severe dysfunction of vital organs such as the heart, liver, or kidneys, which may compromise study outcomes or increase patient risk; 2. Patients with a history of allergy to goserelin or related medications; 3. Patients who have previously undergone menopause due to physiological or pathological factors; 4. Patients with a history of gynaecological conditions (e.g., polycystic ovary syndrome, endometriosis) that may interfere with the assessment of menstrual recovery; 5. Patients currently participating in other clinical studies that may influence menstrual recovery; 6. Patients who refuse to participate in this clinical study.

Sponsors & Collaborators

• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology: lead
• Tongji Hospital: collaborator
• Zhejiang University: collaborator
• The First Affiliated Hospital of Zhengzhou University: collaborator
• The First People's Hospital of Yunnan: collaborator

Study Sites (5)

The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, 450000, China

Location

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, 430000, China

Location

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, 430000, China

Location

The First People's Hospital of Yunnan Province

Kunming, Yunnan, 650000, China

Location

The First Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310000, China

Location

MeSH Terms

Interventions

Goserelin

Intervention Hierarchy (Ancestors)

Gonadotropin-Releasing Hormone; Pituitary Hormone-Releasing Hormones; Hypothalamic Hormones; Peptide Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Neuropeptides; Peptides; Amino Acids, Peptides, and Proteins; Oligopeptides; Nerve Tissue Proteins; Proteins

Central Study Contacts

wei shi

CONTACT

86-13207131315; 496020121@qq.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 20, 2026
• First Posted: April 27, 2026
• Study Start: May 1, 2026
• Primary Completion (Estimated): May 1, 2027
• Study Completion (Estimated): October 1, 2027
• Last Updated: April 27, 2026

Record last verified: 2026-04

Locations

CN (5)